Skip to content

The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection

The Predictive Value of Dynamic Changes of CD4+T Lymphocytes in Primary Nephrotic Syndrome With Infection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104194
Enrollment
Unknown
Registered
2025-06-12
Start date
2022-08-26
Completion date
Unknown
Last updated
2025-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary nephrotic syndrome

Interventions

Gold Standard:Gold standard: Pathogenic microorganisms can be cultured in blood, sputum, urine, etc. Reference standard: clinical manifestations (such as fever, cough, sputum production) Imaging mani
Index test:T lymphocyte subset surveillance

Sponsors

Fifth Affiliated Hospital, Sun Yat-Sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
14 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Age >= 14 years and 3.5g/d); b. Hypoalbuminemia (liver function: albumin<30g/L);c. Edema; d. The blood lipid is elevated. Among them, item a and b are necessary conditions for diagnosis. 3.Renal puncture pathology suggests pathological types of nephrotic syndrome (minimal change glomerulonephropathy, membranous nephropathy, focal segmental glomerulonephritis, membranous proliferative glomerulonephritis, mesangial proliferative glomerulonephritis). 4.Clinically, glucocorticoids or corticosteroids combined with immunosuppressants are required;

Exclusion criteria

Exclusion criteria: 1.Secondary nephrotic syndrome, such as secondary to systemic lupus erythematosus, hepatitis B, hepatitis C, tumor, organic solvent , heavy metal poisoning, etc. 2.Patients with tumors and chronic infectious diseases, such as HIV infection, cardiac insufficiency, acute hepatitis, aminotransferase elevation more than 2 times the normal value, deep vein thromboembolism; 3.The subjects of the study were pregnant and lactating women. 4.Patients with serious primary diseases such as heart, brain, liver and hematopoietic system. 5.Those who are unable to cooperate, such as psychopaths. 6.Known hypersensitivity to or contraindication to any component in glucocorticoids, FK506, MMF, CTX. 7.Serum creatinine (SCr) > 265.2 micromol/L (3 mg/dl);

Design outcomes

Primary

MeasureTime frame
Infection is clinically diagnosed;

Secondary

MeasureTime frame
Symptoms improve and the drug is discontinued;Significant renal failure CKD4, GFR <30ml/(min.173m2);

Countries

China

Contacts

Public ContactZhu Weiping

Fifth Affiliated Hospital, Sun Yat-Sen University

292428893@qq.com+86 756 2528700

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026